Lamotrigine Award
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-D-0013
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the procurement of Lamotrigine Extended Release (ER) Tablets. This notice, identified by procurement number SPE2D2-25-D-0013, pertains specifically to a modification that exercises Option Year 1 of the existing contract, thereby extending the supply arrangement for Lamotrigine ER Tablets. The modification details are available as attachments through the official SAM.gov posting.
The scope of this procurement centers on the continued manufacturing and supply of Lamotrigine ER Tablets, a pharmaceutical product classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and product service code 6505 (Drugs and Biologicals). The place of performance is designated as Brookhaven, New York, ensuring that the manufacturing and distribution activities are localized within the United States.
The primary objective of this contract modification is to maintain a reliable supply of Lamotrigine ER Tablets for federal requirements, supporting the ongoing needs of DLA Troop Support and its stakeholders. Contractors are expected to deliver pharmaceutical-grade products that meet all applicable regulatory and quality standards, consistent with the requirements outlined in the original contract and its subsequent modifications.
The contracting entity is DLA Troop Support, a federal office within the Defense Logistics Agency, which is responsible for sourcing and managing medical and pharmaceutical supplies for the Department of Defense. The notice remains active as of April 28, 2026, and interested parties may review the full details and attachments via the provided SAM.gov opportunity link.
For further information or clarification, contractors may contact the designated representatives: Nancy Fernandez ([email protected], 215-737-4955) or Jason C. Wray ([email protected], 215-737-0614). These contacts serve as the primary and secondary points of communication for this procurement activity.
This award notice does not specify any set-aside requirements or special considerations beyond the exercise of the contract option. The core elements—manufacturing, supply, and quality assurance of Lamotrigine ER Tablets—will remain constant throughout the contract lifecycle, ensuring continuity and compliance with federal pharmaceutical procurement standards.
Contractors with capabilities in pharmaceutical preparation manufacturing, particularly those experienced in producing extended release formulations, may find this opportunity aligns well with their expertise and operational capacity.